Genmab — November 2025
-
-
Godmorgen
-
Nogen har set lyset "Genmab/Rothschild: Hæver kursmålet til 3060 kr. fra 2860 kr.
Genmab har fået hævet sit kursmål til 3060 kr. fra 2860 kr. af finanshuset Rothschild & Co. Redburn.Den positive anbefaling "køb" bliver i samme ombæring gentaget, viser data fra Bloomberg News.
Genmab-aktien lukkede fredag med et fald på 0,6 pct. i 1953,50 kr., hvilket giver et potentiale på 56,7 pct. i forhold til Rothschild & Co. Redburns nye kursmål.
.\˙ MarketWire"
-
TALVEY
▼ (talquetamab) receives positive NICE recommendation in Final Draft Guidance for treating relapsed and refractory multiple myeloma after three or more lines of treatment https://www.jnj.com/innovativemedicine/uk/media-center/press-releases/talvey-talquetamab-receives-positive-nice-recommendation-in-final-draft-guidance-for-treating-relapsed-and-refractory-multiple-myeloma -
Funded by Pfizer and Genmab, this project addresses the urgent barriers faced by patients and clinicians navigating recurrent or metastatic cervical cancer. https://kcmsociety.org/
-
Next-gen treatment keeps myeloma at bay for a year / talquetamab UK https://www.myeloma.org.uk/news/next-gen-treatment-keeps-myeloma-at-bay-for-a-year/
-
The Sub-Q Therapy That Cut Hours Off Treatment Time https://www.curetoday.com/view/the-sub-q-therapy-that-cut-hours-off-treatment-time
-
Servicemeddelelse: Proinvestor.com er desværre periodevis ramt af de verdensomspændende tekniske problemer der er hos Cloudflare for øjeblikket. https://www.dr.dk/nyheder
-
FDA approves epcoritamab-bysp for follicular lymphoma indications https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-epcoritamab-bysp-follicular-lymphoma-indications
-
Genmab henter ny godkendelse til kræftmiddel over for lymfekræftform i USA https://proinvestor.com/investornyt/1384381/genmab-henter-ny-godkendelse-til-kraeftmiddel-over-for-lymfekraeftform-i-usa
-
Genmab cans another ADC from ProfoundBio deal in area of J&J's Ambrx buyout https://endpoints.news/genmab-cans-another-adc-from-profoundbio-deal-in-area-of-jjs-ambrx-buyout/ Endpoint News
Tahi Ahmadi spoke about life cycle management on the Q3 call when asked about SC for Peto, so I sort of thought they would wait a bit with it... But speeding things up makes sense with strong competition
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind